CareDx (CDNA) versus Affymetrix (AFFX) Financial Analysis

CareDx (NASDAQ: CDNA) and Affymetrix (NASDAQ:AFFX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Analyst Ratings

This is a summary of recent recommendations for CareDx and Affymetrix, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx 0 0 3 0 3.00
Affymetrix 0 0 0 0 N/A

CareDx presently has a consensus target price of $7.83, suggesting a potential upside of 32.77%. Given CareDx’s higher possible upside, equities analysts clearly believe CareDx is more favorable than Affymetrix.

Valuation and Earnings

This table compares CareDx and Affymetrix’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
CareDx $46.96 million 2.83 -$9.83 million ($1.44) -4.10
Affymetrix N/A N/A N/A N/A N/A

Affymetrix has higher revenue, but lower earnings than CareDx.

Profitability

This table compares CareDx and Affymetrix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CareDx -61.27% -85.68% -21.21%
Affymetrix 4.24% 4.84% 2.97%

Insider and Institutional Ownership

25.5% of CareDx shares are held by institutional investors. 5.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CareDx beats Affymetrix on 5 of the 8 factors compared between the two stocks.

CareDx Company Profile

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Affymetrix Company Profile

Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply